ES2149159T3 - Proteinas de fusion con contenido en anticuerpos monoclonales, enlazador- y beta-glucuronidasa, destinadas a la activacion de profarmacos, su preparacion y utilizacion. - Google Patents

Proteinas de fusion con contenido en anticuerpos monoclonales, enlazador- y beta-glucuronidasa, destinadas a la activacion de profarmacos, su preparacion y utilizacion.

Info

Publication number
ES2149159T3
ES2149159T3 ES92102197T ES92102197T ES2149159T3 ES 2149159 T3 ES2149159 T3 ES 2149159T3 ES 92102197 T ES92102197 T ES 92102197T ES 92102197 T ES92102197 T ES 92102197T ES 2149159 T3 ES2149159 T3 ES 2149159T3
Authority
ES
Spain
Prior art keywords
beta
hutumab
gluc
fusion proteins
glucuronidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92102197T
Other languages
English (en)
Inventor
Gerhard Seemann
Klaus Bosslet
Jorg Czech
Cenek Kolar
Dieter Hoffmann
Hans-Harald Sedlacek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2149159T3 publication Critical patent/ES2149159T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A UNA PROTEINA DE FUSION QUE SE UTILIZA PARA LA ACTIVACION DE PREDROGAS, Y PRESENTA LA FORMULA (I), SE APLICA EN HUMANOS MEDIANTE LA ASOCIACION DE DICHA PROTEINA CON UN SISTEMA ANTOLOGICO, Y SE OBTIENE POR MEDIO DE LA TECNICA DE GENES, SIENDO (HUTUMAK) UN FRAGMENTO O ANTICUERPO MONOCLONAL ESPECIFICO DE TUMORES HUMANOS; L ES UN LERO QUE UNE (HUTUMAK) CON (BETA)-GLUC PARA NO REDUCIR LAS PROPIEDADES ESPECIFICAS DEL ASOCIADO DE LA PROTEINA Y (BETA)-GLUC, (BETA)-GLUCOROMIDASA HUMANA QUE ACTUA COMO UN COMPUESTO DE PREDROGA APROPIADO A TRAVES DE LA DISOCIACION DEL ACIDO GLUCORONICO.
ES92102197T 1991-02-28 1992-02-10 Proteinas de fusion con contenido en anticuerpos monoclonales, enlazador- y beta-glucuronidasa, destinadas a la activacion de profarmacos, su preparacion y utilizacion. Expired - Lifetime ES2149159T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4106389A DE4106389A1 (de) 1991-02-28 1991-02-28 Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung

Publications (1)

Publication Number Publication Date
ES2149159T3 true ES2149159T3 (es) 2000-11-01

Family

ID=6426148

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92102197T Expired - Lifetime ES2149159T3 (es) 1991-02-28 1992-02-10 Proteinas de fusion con contenido en anticuerpos monoclonales, enlazador- y beta-glucuronidasa, destinadas a la activacion de profarmacos, su preparacion y utilizacion.

Country Status (12)

Country Link
EP (1) EP0501215B1 (es)
JP (1) JP3524933B2 (es)
KR (1) KR100249576B1 (es)
AT (1) ATE193326T1 (es)
AU (1) AU660445B2 (es)
CA (1) CA2062047C (es)
DE (2) DE4106389A1 (es)
DK (1) DK0501215T3 (es)
ES (1) ES2149159T3 (es)
GR (1) GR3033708T3 (es)
IE (1) IE920630A1 (es)
PT (1) PT501215E (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4225853A1 (de) * 1992-08-05 1994-02-10 Behringwerke Ag Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
DE4314556A1 (de) 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
DE19513676A1 (de) * 1995-04-11 1996-10-17 Behringwerke Ag Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli
SI0795334T1 (sl) * 1996-03-12 2006-06-30 Sanofi Aventis Deutschland Predzdravila za zdravljenje tumorjev in vnetnih bolezni
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
EP1113819B1 (en) * 1998-09-18 2011-02-23 Immunomedics, Inc. Antibody directed enzyme prodrug therapy (adept) with glucuronidase
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
WO2005000902A1 (en) * 2003-06-30 2005-01-06 Mu-Hyeon Choe The dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
EP3565843A1 (en) 2017-01-03 2019-11-13 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT80662B (en) * 1984-06-20 1986-12-09 Sanofi Sa Process to obtain anti-tumoral glycoprotein modified on its glycidic portions
FR2591895B1 (fr) * 1985-12-20 1988-08-26 Sanofi Sa Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
ES2075893T3 (es) * 1989-01-23 1995-10-16 Akzo Nobel Nv Activacion in vivo especifica de sede de farmacos terapeuticos.
DE3909799A1 (de) * 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
AU649952B2 (en) * 1989-12-11 1994-06-09 Immunomedics Inc. Method for antibody targeting of diagnostic or therapeutic agents
DE4002888A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Anthracyclin-glycosyl-prodrugs, verfahren zu ihrer herstellung und ihre verwendung in kombination mit funktionalisierten tumorspezifischen enzymkonjugaten

Also Published As

Publication number Publication date
DK0501215T3 (da) 2000-09-18
GR3033708T3 (en) 2000-10-31
DE4106389A1 (de) 1992-09-03
PT501215E (pt) 2000-10-31
ATE193326T1 (de) 2000-06-15
EP0501215B1 (de) 2000-05-24
DE59209839D1 (de) 2000-06-29
CA2062047A1 (en) 1992-08-29
JP3524933B2 (ja) 2004-05-10
AU1125192A (en) 1993-01-28
EP0501215A3 (en) 1993-08-11
KR100249576B1 (ko) 2000-03-15
CA2062047C (en) 2007-12-18
IE920630A1 (en) 1992-09-09
JPH07179500A (ja) 1995-07-18
EP0501215A2 (de) 1992-09-02
AU660445B2 (en) 1995-06-29

Similar Documents

Publication Publication Date Title
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
ES2149159T3 (es) Proteinas de fusion con contenido en anticuerpos monoclonales, enlazador- y beta-glucuronidasa, destinadas a la activacion de profarmacos, su preparacion y utilizacion.
FI100973B (fi) Menetelmä antigeenirakenteiden valmistamiseksi "Major Histocompatibili ty Complex" (MHC) luokka I -antigeeneistä ja monoklonaalisista vasta-a ineista
FI930580A0 (fi) Tri- och tetravalensiska monopecifika antigen bindande proteiner
EP0746398A4 (en) ANTIBODY CLEANING
DE69330643D1 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
DE60025832D1 (de) Mehrere zytokin-antikörper komplexen
FI954347A0 (fi) Monoklonaaliset vasta-ainekoostumukset ja monoklonaalisia vasta-aineita tuottavat hybridomat
ES2115596T3 (es) Recombinados inmunoconjugados para terapias que comprenden interleucina-2.
PT689845E (pt) Conjugados de agentes antitumorais de metiltritio e intermediarios para a sua sintese
AU2349697A (en) Monoclonal antibodies against the interferon receptor with neutralizing activity against type I interferon
DE68925226D1 (de) Monoklonale Antikörper
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
GR3025630T3 (en) Monoclonal antibody against human IgE
EP0683822A4 (en) PRODUCTION OF PHOTOPROTEIN CONJUGATES AND METHOD FOR USE THEREOF.
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
DE69317886D1 (de) Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate
DE69328779D1 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden
DE69611037D1 (de) Methadonderivate und protein- und polypeptid-methadonkonjugate und markierte verbindungen
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
ATE184315T1 (de) Neuartiges endothelzell-molekül, das die bindung von lymphozyten im menschen vermittelt
CA2107329A1 (en) Anti-Human Immunodeficiency Virus Recombinant Antibodies
Marchalonis et al. Introduction—The Immunoglobulin-Like T Cell Receptor Problem
RU94026276A (ru) Рецепторы интерлейкина-12 и антител
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 501215

Country of ref document: ES